32 results about "Vaccine Stability" patented technology

The invention relates a compound adjuvant, which comprises mixed oil (white oil and palm oil) and mixed surfactant (polyoxyethylene oleate, polyoxyethylene alkyl ether and mannitol oleate), specifically (by weight percentage) white oil 70-90, palm oil 1-15, polyoxyethylene oleate 1-10, polyoxyethylene alkyl ether 1-10, and mannitol oleate 1-10. The compound adjuvant is mixed with antigen aqueous solution, and emulsified under stirring to obtain W / O / W type vaccine. The vaccine has the advantages of good stability, little side effects, and high practical application value.

The invention relates to a heatproof freeze-drying protecting agent for recombined pseudorabies virus vaccines. The heatproof freeze-drying protecting agent comprises, by weight, 4-8% of trehalose, 0-3% of cane sugar, 0.2-0.8% of sorbitol, 1-3% of polyvinylpyrrolidone K-30, 4-7% of soybean protein isolate, 0.5-1% of wheat proteolysis product and the balance injection water. The invention further provides a preparation method of the heatproof freeze-drying protecting agent for the recombined pseudorabies virus vaccines. The heatproof freeze-drying protecting agent is simple in formula, easy to prepare and suitable for mass production, has the advantages of high vaccine stability, prolonged vaccine shelf life and the like, and does not contain gelatin and animal source ingredients. Safety of the vaccines is high when the protecting agent is applied to the vaccines.

The invention provides an RNA vaccine for treating non-small cell lung cancer. The nucleotide sequence of the RNA vaccine is shown as SEQ ID NO. 1. The RNA vaccine comprises two parts, namely a basicskeleton sequence (backstone) and a tandem vaccine sequence. The invention further provides a construction method of the RNA vaccine for treating the non-small cell lung cancer. According to the RNA vaccine for treating the non-small cell lung cancer, provided by the invention, a nucleotide sequence of a new antigen is optimally designed by utilizing a codon, connection is carried out by utilizinglinker, insertion of sequences such as SEC and MITD and construction of poly A tails are perfected, plasmids are constructed after sequence design is finished, and a target RNA sequence, namely the new antigen RNA vaccine, is obtained through linearization and in-vitro transcription. The vaccine is good in stability, high in translation efficiency and good in treatment effect, and expression products are easy to transfer.

The invention relates to a preparation method of a triple inactivated vaccine for a Newcastle disease and infectious bronchitis as well as avian flu. The preparation method of the triple inactivated vaccine for the Newcastle disease and the infectious bronchitis as well as the avian flu comprises the following steps of (1), preparing a coexisting seed virus for the Newcastle disease and the infectious bronchitis as well as the avian flu; (2), preparing an antigen; (3), centrifuging the antigen; (4), inactivating the antigen; (5), carrying out emulsification, so as to finally obtain the finished product triple vaccine. According to the preparation method of the triple inactivated vaccine for the Newcastle disease and the infectious bronchitis as well as the avian flu, through optimizing a virus culturing process, the usage amount of chick embryos is decreased; the production cost is reduced; the labor efficiency is improved; the titer of the antigen for three viruses is improved; the concentration is needed for the finished product antigen; the stability and the usage effect of the vaccine are improved.

A freeze-dried carrier vaccine of HIV recombinant MVA virus features high stability. It is prepared from the liquid-type carrier vaccine of HIV recombinant MVA virus through adding the protecting agent prepared from mycose, mannitol, dextran and inositol, stirring and vacuum freeze drying.

The invention provides fusion protein and a nucleotide sequence thereof. The fusion protein comprises a toxoplasma P30 protein subunit and a T cell antigenic epitope. The invention further provides avaccine using the fusion protein to prevent abortion of pregnant sows due to toxoplasmosis and a vaccine composition thereof. The fusion protein has the beneficial effects of the characteristics of high expression quantity and high immunogenicity. The vaccine and the vaccine composition can effectively prevent abortion of the pregnant sows due to the toxoplasmosis and are high in vaccine stability.

The invention relates to a heatproof freeze-drying protecting agent for recombined pseudorabies virus vaccines. The heatproof freeze-drying protecting agent comprises, by weight, 4-8% of trehalose, 0-3% of cane sugar, 0.2-0.8% of sorbitol, 1-3% of polyvinylpyrrolidone K-30, 4-7% of soybean protein isolate, 0.5-1% of wheat proteolysis product and the balance injection water. The invention further provides a preparation method of the heatproof freeze-drying protecting agent for the recombined pseudorabies virus vaccines. The heatproof freeze-drying protecting agent is simple in formula, easy to prepare and suitable for mass production, has the advantages of high vaccine stability, prolonged vaccine shelf life and the like, and does not contain gelatin and animal source ingredients. Safety of the vaccines is high when the protecting agent is applied to the vaccines.

The invention discloses an oil-in-water type vaccine adjuvant as well as a preparation method and application thereof. The oil-in-water type nano-emulsion vaccine adjuvant comprises the following components in percentage by mass: 0.1-10 percent of oil phase, 0.1-10 percent of emulsifier, 0.1-3 percent of stabilizer, 0.1-3 percent of complexing agent and 0.01-10 percent of immunopotentiator. The preparation method comprises the following steps: (1) uniformly dispersing the immunopotentiator, the stabilizer and the complexing agent in water, thereby obtaining an aqueous phase; (2) mixing an oil phase and an emulsifier, thereby obtaining an oil phase; (3) slowly adding the oil phase into the aqueous phase, and continuously stirring, thereby forming a stable emulsion; (4) regulating the pH value of the emulsion, and fixing the volume to obtain a primary emulsion; and (5) performing high-speed shearing and high-pressure homogenizing on the primary emulsion. The vaccine adjuvant provided by the invention is simple in preparation, convenient to use and small in side reactions, is used for diluting vaccines, particularly swine fever live vaccines and is high in stability and good in immune effect.

The invention belongs to the field of biomedicine, and particularly relates to an application of MG132 as a vaccine production synergist and a stabilizing agent. The MG132 can increase the expressionlevel of ribonucleic acid virus structural protein VP3, further promotes the assembly of virus-like particles, and can be applied to virus-like particle expression synergists, virus-like particle production synergists and the stabilizing agents of related vaccines to promote vaccine production and improve vaccine stability.

The invention provides a goat pox virus proliferation method, a goat pox live vaccine and a preparation method and application of the goat pox live vaccine, and relates to the technical field of vaccine preparation. The goat pox virus proliferation method provided by the invention comprises the following steps of carrying out passage domestication on goat pox viruses on a suspension culture cell line to obtain domesticated viruses; carrying out suspension amplification culture on the cell line; and inoculating the domesticated viruses to the cell line subjected to the amplification culture, and performing culture to obtain proliferated viruses. According to the virus proliferation method, large-scale suspension culture of the cell line is realized, the adaptability of the viruses to cellsis improved, and the goat pox viruses with high and stable viral titer can be obtained. The preparation method of the goat pox virus live vaccine provided by the invention is simple in process and lowin cost, and the technical problems of virus damage, poor vaccine stability and short preservation time in a vaccine preparation process are relieved. The goat pox live vaccine provided by the invention is safe and effective, and can be applied to prevention and control of goat pox.

The invention provides a replication-defective Ad29 adenovirus vector as well as a construction method and application thereof. The replication-defective Ad29 adenovirus vector is more efficiently and conveniently prepared through constructing a shuttle plasmid containing a replicon and a resistance gene, preparing an Ad29 adenovirus cyclized plasmid, finding the most suitable knockout site through a CRISPR / Cas9 technology, designing optimal specific targeting gRNA, and specifically knocking out E1 and E3 genes from the Ad29 adenovirus. The adenovirus is low in popularity and low in average neutralization titer in people, can be used for preparing novel coronavirus vaccines, is high in stability, and can be used for inducing very high humoral immunity and cellular immunity.

The invention provides a method for preparing a serum-free cultured suspension mammal cell line, which comprises the following steps: 1)recovering and culturing mammal cells to obtain adherent cultured mammal cells, digesting by pancreatin; 2)culturing the adherent cultured mammal cells by a serum-free medium added with a certain amount of serum, continuously culturing the mammal cells so as to adapt to the serum-free medium with the certain amount of serum; and 3)repeating the continuous cultivation process in the step 2), and gradually reducing the serum addition amount in the serum-free medium until the serum addition in the serum-free medium is 0 to obtain the suspension mammal cell line. According to the method, equalization nutrition of cells is obtained, vaccine stability and uniformity can be guaranteed, and the problems of side effect due to serum addition can be solved, risk due to exogenous pollution is reduced, stress reaction of animal is reduced, and subsequent processing is easy and simple.

The present invention relates to the field of biological products, and in particular relates to a vaccine freeze-drying protective agent containing no gelatin and human albumin. The vaccine freeze-drying protective agent comprises 1.5%-10% of sucrose, 1.5%-3.5% of dextran, 1%-2% of sorbitol, 0.8%-1.2% of sodium glutamate and 0.2% to 1% of L-arginine in a vaccine semi-finished product, a matrix liquid for preparation of the vaccine freeze-drying protective agent is 199 culture medium or PBS buffer solution or water for injection, the vaccine freeze-drying protective agent contains no gelatin and human albumin, and the vaccine semi-finished product is a liquid vaccine before freeze-drying. The present invention also provides the use of the vaccine freeze-drying protective agent. When the vaccine freeze-drying protective agent is used for the preparation of a freeze-dried vaccine, the vaccine freeze-drying protective agent can improve the vaccine stability during freeze-drying and storage processes, greatly improves the freeze-dried vaccine safety for human, and reduces adverse effects of the vaccine.

The invention especially relates to a method for producing a live vaccine against pseudorabies in swine from a continuous cell line, belonging to the technical field of biological products for livestock. The continuous cell line used in the invention is Vero cells. The method comprises the following steps: passage and culture of cells for vaccine preparation; propagation of virus seeds of the cells; propagation of virus liquid used for vaccine preparation; and vaccine preparation, split charging and freeze-drying. Porcine pseudorabies viruses obtained by using the method re high in content and titer; and the eventually prepared vaccine has high stability and long shelf life.

The invention discloses an immunogenic composition containing rabbit staphylococcus antigen, a preparation method and application thereof. The immunogenic composition comprises a mixture of rabbit staphylococcus antigen, dispersion carrier and aqueous printing adjuvant as a printing spray liquid , and the freeze-dried protective powder is used as the coating powder, and the printing spraying liquid is repeatedly sprayed on each layer of the coating powder by using the 3DP printing technology to obtain a three-dimensional structure of the immunogenic composition containing the rabbit staphylococcus antigen. The immunogenic composition prepared by the method of the invention has good immunogenic activity and immune protection, can be effectively used for the prevention and treatment of rabbit Staphylococcus aureus, the immune protection rate is as high as 100%, and the vaccine has good stability and is not easy to be inactivated.

The invention relates to a preparation method of a triple inactivated vaccine for a Newcastle disease and infectious bronchitis as well as avian flu. The preparation method of the triple inactivated vaccine for the Newcastle disease and the infectious bronchitis as well as the avian flu comprises the following steps of (1), preparing a coexisting seed virus for the Newcastle disease and the infectious bronchitis as well as the avian flu; (2), preparing an antigen; (3), centrifuging the antigen; (4), inactivating the antigen; (5), carrying out emulsification, so as to finally obtain the finished product triple vaccine. According to the preparation method of the triple inactivated vaccine for the Newcastle disease and the infectious bronchitis as well as the avian flu, through optimizing a virus culturing process, the usage amount of chick embryos is decreased; the production cost is reduced; the labor efficiency is improved; the titer of the antigen for three viruses is improved; the concentration is needed for the finished product antigen; the stability and the usage effect of the vaccine are improved.